Piramal Pharma Share Price Target 2025, 2026, 2030, 2040, 2050
Piramal Pharma Ltd, an India-based pharmaceutical company, manufactures high-quality medicines for hospitals and individual healthcare needs, such as skin care products, vitamins, pain relievers and baby care products. The company was founded in 1988 with the acquisition of Nicholas Laboratories from France. The headquarters are currently located in Mumbai, and the company operates globally, providing quality healthcare.
This blog will provide the details of Piramal Pharma Share Price targets as far as 25 years from now (2025 – 2050) based on its fundamentals, market position, and growth potential.
What is Piramal Pharma Ltd NSE: PPLPHARMA?
Piramal Pharma operates in three key areas, namely Contract Development and Manufacturing (CDMO), Hospital Generics (CHG) and Consumer Healthcare (ICH). With 15 manufacturing sites serving regulated markets such as the US, Europe and Japan, strong brands and continuous growth initiatives, Piramal aims to become a global leader in pharmaceuticals and wellness by 2030.
Fundamental Data
| Metric | Value |
|---|---|
| Market Cap | ₹27,755 Cr. |
| 52-Week High/Low | ₹308 / ₹114 |
| Stock P/E | 529 |
| Industry P/E | 29.9 |
| Book Value | ₹59.6 |
| Price to Book Value | 3.48 |
| Dividend Yield | 0.05% |
| ROCE | 5.49% |
| ROE | 0.22% |
| EPS | ₹0.30 |
| Net Profit | ₹38.9 Cr. |
| PBT (Annualized) | ₹179 Cr. |
| Debt | ₹4,786 Cr. |
| Debt to Equity | 0.61 |
| Promoter Holding | 35.0% |
| Current Liabilities | ₹5,237 Cr. |
| Current Assets | ₹5,382 Cr. |
| Net Cash Flow (PY) | ₹-32 Cr. |
Peer Comparisons
| S.No. | Company Name | CMP (₹) | P/E | Market Cap (₹Cr.) | Dividend Yield (%) | Net Profit (Qtr) (₹Cr.) | Qtr Profit Var (%) | Sales (Qtr) (₹Cr.) | Qtr Sales Var (%) | ROCE (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sun Pharma | 1644.90 | 33.43 | 3,94,667 | 0.81 | 2,912.98 | 22.66 | 13,675.46 | 10.46 | 17.32 |
| 2 | Cipla | 1476.30 | 23.95 | 1,19,228 | 0.87 | 1,574.59 | 31.37 | 7,072.97 | 7.10 | 22.80 |
| 3 | Mankind Pharma | 2329.50 | 49.71 | 96,110 | 0.00 | 416.38 | -10.01 | 2,396.57 | 8.48 | 24.57 |
| 4 | Dr. Reddy’s Labs | 1151.70 | 17.92 | 96,103 | 0.68 | 1,404.20 | 1.69 | 8,381.20 | 15.81 | 26.53 |
| 5 | Zydus Lifesciences | 886.00 | 19.67 | 89,152 | 0.33 | 1,026.20 | 33.34 | 5,269.10 | 16.96 | 22.34 |
| 6 | Lupin | 1904.95 | 30.35 | 86,957 | 0.39 | 858.86 | 39.48 | 5,767.71 | 10.97 | 15.72 |
| 7 | Aurobindo Pharma | 1117.50 | 18.41 | 65,479 | 0.40 | 845.57 | -9.69 | 7,978.52 | 8.53 | 14.10 |
| 8 | Piramal Pharma | 209.35 | 528.74 | 27,754 | 0.05 | 3.68 | -59.16 | 2,204.22 | 12.54 | 5.49 |
| Period | Share Price (INR) |
|---|---|
| Before 1 Year | ₹134.60 |
| Before 6 Months | ₹187.23 |
| Before 5 Years | ₹167.47 |
| All-Time Max | ₹308.00 |
The company operates in hospital generics, pharma manufacturing, and consumer healthcare. However, its financials are weak – the PE ratio is 529, its debt is ₹4,786 Cr, and its profit is low. If positive news comes, the stock might rise a bit; otherwise, there will not be much movement. Best for long-term investors. The price may fluctuate tomorrow, but the long-term growth potential remains strong.
| Day | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| Tomorrow | -12 from today’s price | +20 from today’s price |
PPLPHARMA Indicator Based Technical Analysis
NOTE!
Signals may differ across timeframes. If you’re planning to purchase PPLPHARMA and keep it for more than one week, it’s suggested that you choose signals from weekly and daily timeframes. For trading in the short term, signals that range from 5 minutes to 1-hour timeframes are better appropriate.
The company has established itself as a strong presence in the pharmaceutical sector with three key segments: Contract Development and Manufacturing Operations (CDMO), Complex Hospital Generics (CHG) and India Consumer Healthcare (ICH). With the increasing demand for high-quality pharmaceuticals and healthcare products, Piramal is expected to flourish by 2025 as it expands into regulated markets such as the US, Europe and Japan.
Our analysis shows that the share price is expected to be between Rs 145 and Rs 325.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2025 | 145 | 325 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 145 | 210 |
| February | 150 | 220 |
| March | 155 | 230 |
| April | 160 | 240 |
| May | 170 | 250 |
| June | 180 | 260 |
| July | 190 | 270 |
| August | 200 | 280 |
| September | 210 | 290 |
| October | 230 | 300 |
| November | 250 | 310 |
| December | 275 | 325 |
The company’s Contract Development and Manufacturing Organization (CDMO) segment is a key source of growth. They support pharmaceutical companies in the development and manufacture of medicines. With 15 CDMO locations in India, the USA and Europe, Piramal Pharma is one of the three largest CDMO providers and is an indispensable service provider with over 500 customers worldwide. The increasing demand for “integrated projects” also contributes to its future success.
Our analysis shows that the share price is expected to be between Rs 180 and Rs 450.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2026 | 180 | 450 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 180 | 260 |
| February | 190 | 275 |
| March | 200 | 290 |
| April | 210 | 310 |
| May | 225 | 330 |
| June | 240 | 350 |
| July | 260 | 370 |
| August | 280 | 390 |
| September | 300 | 410 |
| October | 320 | 430 |
| November | 340 | 440 |
| December | 370 | 450 |
The company’s Complex Hospital Generics (CHG) segment is expected to expand significantly by 2030. CHG supplies critical care medicines, including anesthesia, pain management, and specialty drugs. It currently accounts for 30% of Piramal’s sales and is the fourth largest manufacturer of inhaled anesthesia products globally. With increasing demand from hospitals and improved access to healthcare, this segment will become a key growth driver over time.
Our analysis shows that the share price is expected to be between Rs 650 and Rs 975.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2030 | 650 | 975 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 650 | 720 |
| February | 670 | 740 |
| March | 690 | 765 |
| April | 710 | 790 |
| May | 730 | 815 |
| June | 750 | 840 |
| July | 770 | 860 |
| August | 790 | 885 |
| September | 810 | 910 |
| October | 835 | 935 |
| November | 860 | 955 |
| December | 890 | 975 |
Piramal Pharma’s India Consumer Healthcare (ICH) division will play an important role in 2040 as the ICH division boasts of well-known brands such as Lacto Calamine, Tetmosol Polycrol and Little’s Baby Care. The company is pursuing an “asset light” model that does not require large investments for growth. The company has launched more than 150 new products in three years, ensuring a strong market presence while adapting to the increasing demand for health and wellness products. The company’s ICH division will continue to be an excellent revenue generator in 2040.
Our analysis shows that the share price is expected to be between Rs 1,775 and Rs 2,345.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2040 | 1775 | 2345 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 1775 | 1850 |
| February | 1800 | 1880 |
| March | 1840 | 1930 |
| April | 1890 | 1980 |
| May | 1940 | 2045 |
| June | 1995 | 2100 |
| July | 2050 | 2165 |
| August | 2110 | 2220 |
| September | 2170 | 2275 |
| October | 2225 | 2300 |
| November | 2250 | 2325 |
| December | 2275 | 2345 |
By 2050, The company is likely to be a global leader in pharmaceuticals and healthcare. The company is actively expanding its production capacity and entering into partnerships. The company owns a stake in Japan Bio, which strengthens the biologics business, and the new facility in Kentucky, USA, will increase production. With its strong focus on quality, innovation, and global expansion, Piramal Pharma has the opportunity to achieve long-term and sustainable growth in the healthcare industry.
Our analysis shows that the share price is expected to be between Rs 4,365 and Rs 5,230.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2050 | 4365 | 5230 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 4365 | 4500 |
| February | 4450 | 4600 |
| March | 4550 | 4700 |
| April | 4650 | 4800 |
| May | 4750 | 4900 |
| June | 4850 | 5000 |
| July | 4950 | 5100 |
| August | 5000 | 5150 |
| September | 5050 | 5180 |
| October | 5100 | 5200 |
| November | 5150 | 5220 |
| December | 5180 | 5230 |
| Shareholder Type | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|
| Promoters | 34.94% | 34.94% | 34.94% | 35.02% |
| FIIs (Foreign Investors) | 31.68% | 31.73% | 31.41% | 30.58% |
| DIIs (Domestic Investors) | 14.09% | 13.80% | 12.95% | 12.12% |
| Public | 18.85% | 19.06% | 20.20% | 21.89% |
| Others | 0.40% | 0.45% | 0.47% | 0.37% |
Alembic Share Price Target 2025, 2026, 2030, 2040, 2050
Should I Buy Piramal Pharma Stock?
The promoter stake of the company is stable (34.94%), interest from FIIs is fluctuating (~31%), and Indian investors (DIIs) are increasing their stake (12.12% to 14.09%). Public shareholding is reduced. The stock is risky but good for long-term investors. Not for quick profits!
Piramal Pharma Ltd Earning Results (Financials)
| Year | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Sales | 8,949 | 8,171 | 7,082 | 6,559 | 6,315 |
| Expenses | 7,536 | 6,974 | 6,453 | 5,609 | 4,887 |
| Operating Profit | 1,414 | 1,197 | 629 | 950 | 1,428 |
| OPM % | 16% | 15% | 9% | 14% | 23% |
| Other Income | 157 | 172 | 272 | 319 | 230 |
| Interest | 432 | 448 | 344 | 198 | 163 |
| Depreciation | 770 | 741 | 677 | 586 | 545 |
| Profit Before Tax | 369 | 179 | -120 | 485 | 949 |
| Tax % | – | 90% | 55% | 22% | 12% |
| Net Profit | 39 | 18 | -186 | 376 | 835 |
| EPS (₹) | 0.30 | 0.13 | -1.41 | – | – |
| Dividend Payout % | – | 82% | 0% | 18% | 0% |
Expert Forecasts On The Future Of Piramal Pharma Ltd.
The company’s sales are growing, but profits are weak due to high costs and loans. Experts say the share cannot deliver quick returns. If earnings improve, long-term investors can benefit. Short-term traders, be careful. If earnings remain low, the stock will remain dull. Long-term patience required
Is Piramal Pharma Stock Good to Buy? (Bull case & Bear case)
Bullish Case:
- Growing sales, turnover increases steadily
- Strong business with pharmaceuticals, hospital generics and CDMO
- Project sponsor remains stable, shows confidence
- Long-term potential if profits improve
Bearish Case:
- High debt burden of ₹4.786 cr.
- Weak profits, high expenses
- Very expensive stock with a price-earnings ratio of 529
- Share can remain cloudy without strong profits
- Risky in the short term, better for patient long-term investors!
Conclusion
Piramal Pharma has a strong pharmaceutical business with CDMO, hospital generics (CHG) and consumer healthcare (ICH). CDMO brings in a lot of money, and the Indian market is growing. But profits are weak, and debt is high. Short-term growth looks slow, but long-term expansion and better profits can bring solid returns. If you’re considering an investment, you should read the full article for details about the company’s performance and future stock projections.
Dr Agarwal Healthcare Share Price Target 2025, 2026, 2030, 2040, 2050
